In disappointing news for Merck the drug maker released results of an interim study data showing a triple combination treatment  which includes two of its own compounds and the bigselling Sovaldi medication  came up short Merck hoped the regimen would cut treatment durations in half  to just four weeks  but the data shows the combination came nowhere close due to a high relapse rate The results which were released at a meeting of the American Association for the Study of Liver Diseases underscore the difficulty the drug maker may have in competing widely in the burgeoning hepatitis C market